Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Phase 2

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Cytarabine

First Posted Date: 2018-01-26

Last Posted Date: 2022-04-20

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 50

Registration Number: NCT03412266

Locations: 🇨🇳
Peking University Institute of Hematology,Beijing, Beijing, Beijing, China

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Phase 2

Recruiting

Conditions: Myelodysplastic Syndromes
Acute Leukemia

Interventions: Drug: Cytarabine

First Posted Date: 2018-01-26

Last Posted Date: 2024-03-26

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 50

Registration Number: NCT03412409

Locations: 🇨🇳
Peking University, Institute of Hematolgoy, Beijing, China

CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML

Phase 3

Conditions: High Risk Acute Myeloid Leukemia
Allogeneic Hematopoeitic Stem Cell Transplantation

Interventions: Drug: Cladribine
Drug: Fludarabine
Drug: Busulfan
Drug: Cytarabine

First Posted Date: 2017-12-27

Last Posted Date: 2021-10-12

Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 120

Registration Number: NCT03384212

Locations: 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China

CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

Phase 3

Conditions: Allogeneic Hematopoeitic Stem Cell Transplantation
High Risk Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Fludarabine
Drug: Busulfan
Drug: Cytarabine

First Posted Date: 2017-12-27

Last Posted Date: 2021-10-12

Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 120

Registration Number: NCT03384225

Locations: 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Daratumumab
Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin
Biological: Peg-asparaginase
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: 6-mercaptopurine
Drug: Methotrexate

First Posted Date: 2017-12-27

Last Posted Date: 2023-12-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 47

Registration Number: NCT03384654

Locations: 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

and more 50 locations

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Phase 2

Conditions: Acute Myeloid Leukemia
P53 Mutation

Interventions: Drug: Decitabine
Drug: Arsenic Trioxide
Drug: Cytarabine

First Posted Date: 2017-12-22

Last Posted Date: 2018-01-04

Lead Sponsor: Li Junmin

Target Recruit Count: 100

Registration Number: NCT03381781

Locations: 🇨🇳
Shanghai Institute of Hematology, Shanghai, China
🇨🇳
Ruijin Hospital North, Shanghai, China
🇨🇳
Ruijin Hospital, Shanghai, China

Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Nivolumab
Biological: G-CSF mobilized HLA-haploidentical donor PBSC

First Posted Date: 2017-12-21

Last Posted Date: 2019-04-05

Lead Sponsor: St. Petersburg State Pavlov Medical University

Target Recruit Count: 16

Registration Number: NCT03381118

Locations: 🇷🇺
Boris V Afanasyev, MD, Prof., Saint Petersburg, Russian Federation

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Cytarabine

First Posted Date: 2017-12-20

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 301

Registration Number: NCT03379727

Locations: 🇸🇪
Novartis Investigative Site, Uppsala, Sweden

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Phase 2

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Cytarabine
Drug: All-transretinoic acid
Drug: G-CSF

First Posted Date: 2017-11-29

Last Posted Date: 2017-11-29

Lead Sponsor: Shanghai Tong Ren Hospital

Target Recruit Count: 50

Registration Number: NCT03356080

Locations: 🇨🇳
The center hospital of Shanghai Fengxian District, Shanghai, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳
First Affiliated Hospital of Zhengzhou University., Zhengzhou, China

and more 3 locations

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Phase 1

Completed

Conditions: Refractory Acute Lymphoblastic Leukemia
Relapsed Acute Lymphoblastic Leukemia

Interventions: Drug: Pevonedistat
Drug: Vincristine
Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Hydrocortisone

First Posted Date: 2017-11-21

Last Posted Date: 2022-10-20

Lead Sponsor: Julio Barredo, MD

Target Recruit Count: 6

Registration Number: NCT03349281

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy